PASTIC Dspace Repository

Assessment of potential interaction between simvastatin and clarithromycin in healthy adult male subjects

Show simple item record

dc.contributor.author Zainab Kaleem
dc.contributor.author Khan, Junaid Ali
dc.contributor.author Zahid Mushtaq
dc.contributor.author Sidra Altaf
dc.contributor.author Ijaz Javed
dc.date.accessioned 2023-01-20T07:05:50Z
dc.date.available 2023-01-20T07:05:50Z
dc.date.issued 2018-05-10
dc.identifier.citation Kaleem, Z., Khan, J. A., Mushtaq, Z., Altaf, S., & Javed, I. (2018). Assessment of potential interaction between simvastatin and clarithromycin in healthy adult male subjects. Pakistan Journal of Pharmaceutical Sciences, 31(3), 801-807. en_US
dc.identifier.issn 1011-601X
dc.identifier.uri http://142.54.178.187:9060/xmlui/handle/123456789/16337
dc.description.abstract Cardiac patients with weak immune system are susceptible to bacterial infections. Their prescriptions frequently contain simvastatin and clarithromycin together. The objective of present project was to assess the potential interaction between simvastatin and clarithromycin by evaluating the clarithromycin effects on the pharmacokinetics of simvastatin in healthy adult male subjects. The study design comprised of two phases, used at interval of one week. In first phase simvastatin 20 mg alone was administered to each volunteer. In second phase, co-administration of simvastatin 20 mg with clarithromycin 250 mg was made under similar specified conditions. Blood samples were collected at specified time intervals. Simvastatin plasma concentrations were analyzed through High Performance Liquid Chromatography with UV detector at 238 nm wavelength. Using one compartment open model, MW/PHARM version 3.02 software program was used by F. Rombut for pharmacokinetic parameters calculation. Clarithromycin co-treatment resulted in 2.3 fold increase in maximum plasma concentration Cmax (from 2.47±0.34 ng.mL-1 to 5.66±1.18 ng.mL-1; p<0.05) and 3.9 fold increase in area under time versus concentration curve from 0 to 10 hours AUC0-10 (from 15.10±3.73 ng.hr.mL-1 to 58.49±15.73 ng.hr.mL-1; p<0.05) of simvastatin. These results suggest that co-prescription of simvastatin and clarithromycin should be avoided to minimize the adverse events resulting from high simvastatin concentration, without sacrificing therapeutic worth of simvastatin. en_US
dc.language.iso en en_US
dc.publisher Karachi: Faculty of Pharmacy & Pharmaceutical Sciences University of Karachi en_US
dc.subject Simvastatin en_US
dc.subject plasma en_US
dc.subject plasma en_US
dc.subject clarithromycin en_US
dc.subject HPLC en_US
dc.subject pharmacokinetic interaction en_US
dc.title Assessment of potential interaction between simvastatin and clarithromycin in healthy adult male subjects en_US
dc.type Article en_US


Files in this item

This item appears in the following Collection(s)

Show simple item record

Search DSpace


Advanced Search

Browse

My Account